As illustrated in Figure 7, the current study showed, for the first time, that the synthetic dual GPR40/GPR120 agonist GW9508 alleviated alveolar bone loss and periodontal inflammation in mice with MetS-associated periodontitis. Here, FFAR1 is linked to metabolic syndrome.